The conversation discusses the availability of Breezula, a drug for hair loss, now being sold as an acne treatment, and whether it can be applied to the scalp. Users express skepticism about new hair loss treatments and suggest waiting for FDA approval.
Akinfenrawr experienced negative side effects from oral finasteride and RU58841, and is seeking alternative hair loss treatments. They discuss various options, including raloxifene, oral dutasteride, liposomal finasteride, Breezula, Pyrilutamide, SM04554, and sulforaphane, but have concerns about efficacy, availability, and cost.
The conversation discusses concerns about potential side effects, specifically gynecomastia, from taking 1mg of finasteride every other day for hair loss. Bloodwork results were shared, but more information was requested to provide advice.
The user is considering Botox for scalp hair loss and currently uses finasteride, minoxidil, microneedling, pumpkin seed oil, saw palmetto, and green tea extract. They seek information on potential risks and effectiveness.
User started hair loss treatment 3 months ago using topical fin, minoxidil, RU58841, stemoxydine, and microneedling. Others noticed improvement in mid and frontal scalp areas and suggested considering oral minoxidil.
Hair loss treatment using 1mg Fin daily and Nizoral shampoo twice a week for 10 months showed improvement after 6-10 months. No significant side effects experienced, except slightly watery semen.
The conversation discusses experiences with topical dutasteride for hair loss, comparing formulations from FUEClinic, MinoxidilMax, and Strut. Users share their results and side effects, with some preferring topical over oral treatments to minimize systemic absorption.
The user shared their hair loss treatment progress using minoxidil, ketoconazole shampoo, a dermaroller, biotin, Pura d'or shampoo, and Propidren. They apply minoxidil daily, take Propidren and biotin pills, use two types of shampoo, and use a dermaroller weekly, avoiding finasteride due to concerns about side effects.